Clinical Trial Update: Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303 [Phase 3]

View source ↗

Summary

Phase 3 safety study of etripamil nasal spray for paroxysmal supraventricular tachycardia has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Supraventricular Tachycardia

Drugs mentioned

• etripamil nasal spray (etripamil)

Snippet

Sponsor: Milestone Pharmaceuticals Inc. | Conditions: Paroxysmal Supraventricular Tachycardia | Phase 3 | Status: COMPLETED | Results posted: 2024-05-23